Assembly Biosciences Puts a Bigger Bet on the Liver — and Lets Gilead Decide How Much It Gets to Win

Assembly Biosciences widens ABI-6250 to PBC/PSC, advances Gilead-partnered GS-1179, and posts narrowed Q2 loss with cash runway into 2029.

The second-quarter scorecard that Assembly Biosciences filed with the SEC on August 13 was about more than just a shrinking loss. Tucked inside the numbers was a strategic shift: the biotech is widening its oral NTCP inhibitor ABI-6250 into cholestatic liver disease, adding primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) to a program previously aimed squarely at chronic hepatitis delta.

That expansion, backed by positive Phase 1a data, gives the candidate a second runway beyond its original indication. A Phase 2 basket study in PBC and PSC is slated to begin in the first quarter of 2027, with initial readouts expected in the first half of 2028. Meanwhile, the hepatitis delta Phase 2 trial is still targeted to start before the end of this year, with results due in the fourth quarter of 2027.

The Gilead Relationship Keeps Paying — and Posing a Question

The partnership with Gilead Sciences remains the financial engine. Collaboration revenue climbed to $13.4 million in the second quarter, up from $9.6 million a year earlier. More significantly, Gilead has selected GS-1179 — formerly ABI-1179 — for advancement into a Phase 2 study in recurrent genital herpes, with the trial start expected later this year. The development plan also includes evaluating the candidate in combination with HIV pre-exposure prophylaxis.

That progress triggers a $75 million extension payment from Gilead, due in the fourth quarter of 2026 to mark the third anniversary of the collaboration. It is a welcome addition to a balance sheet that already looks sturdy: cash and securities stood at $320.4 million as of June 30, up from $226.6 million three months earlier, thanks to a $115 million gross capital raise completed in May that involved nearly 3.9 million shares at $26.50 each plus pre-funded warrants.

The company projects that war chest will fund operations into 2029, removing any near-term pressure to tap the markets again.

The bigger strategic question, though, is whether Assembly will exercise its option to take a 40% share of US costs and profits on GS-1179. Management has said it will decide only after receiving Gilead's commercial cost estimates. Opt in, and the company participates meaningfully in any eventual market success. Opt out, and it is left with milestones and royalties — a smaller slice of a potentially large pie.

The Numbers Are Moving in the Right Direction

The income statement is starting to cooperate. Research and development spending eased to $14.9 million from $16.1 million in the year-ago period, while the net loss narrowed to $3.9 million, or 20 cents per share, from $10.2 million, or $1.33 per share. The share count has risen to roughly 20.4 million following the capital increase.

The stock has taken notice. Shares closed Wednesday at $32.75, up 1.9% on the day. Over the past month, the equity has gained 24%, and it is up 25% over twelve months. That rally has pushed the price about 24% above its 50-day moving average of $26.49, a sign of how quickly sentiment has shifted. Still, the stock sits roughly 18% below its 52-week high of $39.71, reached on November 20, and remains down 3.7% year to date.

Bulls See a Catalyst Chain; Bears See a Crowded Trade

Optimists point to a rare combination: rising partner revenue, a contracting loss, and a pipeline that keeps broadening. H.C. Wainwright's Patrick Trucchio reiterated a Buy rating on Tuesday with a $50 price target, citing the ABI-6250 expansion and the cash runway into 2029. Guggenheim followed with a $43 target on August 16.

The bull case rests on a sequence of upcoming catalysts: the $75 million Gilead payment in Q4, the Phase 2 starts for GS-1179 in genital herpes and ABI-6250 in hepatitis delta by year-end, and the PBC/PSC basket study early next year. Execute on those, and the current valuation could look like an early entry point into a multi-year story.

The bear case is equally straightforward. The stock has climbed 31% in 30 days, and the relative strength index sits at 67.4 — approaching overbought territory. Should the Gilead cost estimates disappoint, or should Assembly decide against the US profit-sharing opt-in, the recent premium could evaporate quickly. And the Phase 2 starts, while imminent, remain announcements rather than completed facts; delays in early-stage clinical work are hardly unusual.

What Happens Next

The immediate test comes in the fourth quarter, when the $75 million extension payment lands. After that, all eyes turn to the year-end study starts and, eventually, the opt-in decision on US cost-sharing. The company will also be making the rounds at medical conferences — the ACS fall meeting in Chicago in late August, the International HBV Meeting in Singapore in September, ID Week in Washington in October, and the AASLD gathering in Denver in November — where the expanded pipeline gets its first public airings.

For now, the balance sheet buys time, the partner is engaged, and the pipeline has more shots on goal than it did a quarter ago. Whether that translates into lasting shareholder value depends on decisions that have yet to be made — and data that has yet to be read.